Gilead Sciences Return on Equity

Gilead Sciences (GILD.SW) currently reports a ROE of -29.63%. That is below the Healthcare sector average of 13.26%. Use the charts on this page to explore Gilead Sciences's ROE history and peer comparisons.

Gilead Sciences's ROE of -29.63% is lower than the Healthcare sector average of 13.26%. That is roughly 323.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Gilead Sciences's current -29.63% should be judged against Healthcare norms (sector average: 13.26%) and against GILD.SW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -29.63%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.26%. From there, open related valuation or income-statement pages for Gilead Sciences, and consider following GILD.SW for alerts when major investors trade the stock.

Gilead Sciences is classified in the Healthcare sector. On ROE, it currently shows -29.63% versus a sector average near 13.26%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GILD.SW with unrelated industries.